Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: Results of a phase II nonrandomized expansion study

Matthew R. Smith*, Christopher J. Sweeney, Paul G. Corn, Dana E. Rathkopf, David C. Smith, Maha Hussain, Daniel J. George, Celestia S. Higano, Andrea L. Harzstark, A. Oliver Sartor, Nicholas J. Vogelzang, Michael S. Gordon, Johann S. De Bono, Naomi B. Haas, Christopher J. Logothetis, Aymen Elfiky, Christian Scheffold, A. Douglas Laird, Frauke Schimmoller, Ethan M. BaschHoward I. Scher

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

97 Scopus citations

Fingerprint

Dive into the research topics of 'Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: Results of a phase II nonrandomized expansion study'. Together they form a unique fingerprint.

Medicine & Life Sciences